Objective: Olanzapine long-acting injection depot (OLAI) has been licensed in the UK since 2008. As a result of the recognition during clinical trials that in 0.07% of injections there may be inadvertent intravenous administration leading to post-injection delirium/sedation syndrome (PDSS), the licence mandates a 3 h observation after each injection and accompaniment of the patient to their final destination. The administration of OLAI may thus necessitate organization of local service provisions. We report on how a single healthcare facility in Northern Ireland has treated three initial patients and present a brief case series on these patients and their clinical outcomes.
Methods: In the first three patients with schizophrenia to receive OLAI, the clinical notes were retrospectively examined to provide clinical data.
Results: All three patients had acceptable clinical outcomes showing sustained clinical improvement and have continued on OLAI for over 1 year. Observation has been undertaken within an existing daycare unit staffed by nursing staff and occupational therapists for 3 h after each injection. No issues have emerged from the use of this service that has also provided educational and psycho-educational programmes for the patients. No cases of post-injection delirium/sedation syndrome were reported. There have been no additional cost implications.
Conclusions: In patients for whom OLAI may be clinically indicated, the utilization of an existing service to provide the 3 h of observation after each injection may represent a solution with a cost-neutral outcome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736945 | PMC |
| http://dx.doi.org/10.1177/2045125312446395 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Practices and attitudes of adult psychiatrists regarding methamphetamine-associated psychotic disorder: an internet based survey conducted in Turkey.
BMC Health Serv Res
January 2025
Department of Psychiatry, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey.
Background: Many variables may affect approaches of psychiatrists to methamphetamine-associated psychotic disorder (MAP) treatment. This study was aimed to reach adult psychiatrists actively practicing in Turkey through an internet-based survey and to determine their practices and attitudes to MAP treatment.
Methods: In this internet-based study, participants were divided into three groups based on their answers: Those who do not follow-up any MAP patient were group 1 (n = 78), partially involved in the treatment process of at least one patient diagnosed with MAP were group 2 (n = 128), completely involved in the treatment process of at least one patient diagnosed with MAP were group 3 (n = 202).
Cost-effectiveness of ten commonly used antipsychotics in first-episode schizophrenia in the UK: economic evaluation based on a discrete event simulation model.
Br J Psychiatry
December 2024
Public Health Department, Aix Marseille University, Marseille, France.
Background: Previous economic evidence about interventions for schizophrenia is outdated, non-transparent and/or limited to a specific clinical context.
Aims: We developed a discrete event simulation (DES) model for estimating the cost-effectiveness of interventions in schizophrenia in the UK.
Method: The DES model was developed based on the structure of previous models, populated with demographic, clinical and cost data from the UK, and antipsychotics' effects from recent network meta-analyses.
Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000-2019: 20-year investigation of who receives treatment, with which agents and at what doses.
Br J Psychiatry
December 2024
Division of Psychiatry, University College London, London, UK.
Background: Contemporary data relating to antipsychotic prescribing in UK primary care for patients diagnosed with severe mental illness (SMI) are lacking.
Aims: To describe contemporary patterns of antipsychotic prescribing in UK primary care for patients diagnosed with SMI.
Method: Cohort study of patients with an SMI diagnosis (i.
Initiation of Antipsychotics During the First Year After First-Episode Psychosis: A Population-Based Study.
Acta Psychiatr Scand
November 2024
Niuvanniemi Hospital, Kuopio, Finland.
Background: Antipsychotics are recommended after first-episode psychosis. Knowledge on the current use patterns in real-world settings is thus important to inform clinical practice. We aimed to describe antipsychotic initiation during 1 year after first-episode psychosis and its associated factors.
View Article and Find Full Text PDFCurrent status and features of antipsychotic prescriptions in Japanese forensic psychiatric wards based on a forensic inpatient database.
Neuropsychopharmacol Rep
March 2025
Department of Forensic Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
Article Synopsis
- Psychopharmacotherapy is crucial for treating mentally disordered offenders (MDOs) with schizophrenia in Japan, highlighting a lack of large-scale research in forensic settings.
- The study analyzed data from 362 MDOs across 32 forensic psychiatric wards, focusing on the use of antipsychotic medications, particularly clozapine and long-acting injections (LAIs).
- Findings showed that clozapine and LAIs were used in about 23% and 25% of cases, respectively, with clozapine linked to higher seclusion rates and longer hospital stays, indicating a need for further research on medication impacts in this population.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!